Aussie biopharma outfit NeuClone Pharmaceuticals announces plans to enter the clinic with its biosimilar to Johnson & Johnson’s (JNJ +0.3%) Stelara (ustekinumab), branded as NeuLara.

A Phase 1 study in Australia should launch in H2.

The company just completed dosing in another Phase 1 study assessing its biosimilar to Roche’s (OTCQX:RHHBY) Herceptin (trastuzumab), branded NeuCeptin.

It is also working on biosimilars to Amgen’s (AMGN +1.3%) Prolia/XGEVA (denosumab), AstraZeneca’s (AZN -0.4%) Synagis (palivizumab) and Roche’s Perjeta (pertuzumab).